Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabien Tech. Regulatory News (SNT)

Share Price Information for Sabien Tech. (SNT)

Share Price is delayed by 15 minutes
Get Live Data
3.25    0.00 (0.00%)
Bid:
3.00
Ask:
3.50
Spread: 0.50 (16.667%)
Market Cap: £1.03m
SNT Live PriceLast checked at - London Stock Exchange

Intraday Sabien Tech. Share Chart

Trading Update

7 Jul 2022 07:00

RNS Number : 6041R
Sabien Technology Group PLC
07 July 2022
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310.

7 July 2022

 

Sabien Technology Group plc

("Sabien", the "Company", or the "Group")

Trading Update

Sabien Technology Group plc (AIM:SNT), the company focused on a green aggregation strategy, announces today a trading update ahead of the publication of its final results for the year ended 30 June 2022.

During the year ended 30 June 2022, Sabien's Green Aggregation Strategy has focussed on three principal technology-led initiatives. M2G, the existing Sabien CO2 mitigation device for commercial boilers, the UK rollout of Proton's oil to hydrogen technology, and the COF plastic to oil technology. 

M2G Business

Despite the world semiconductor supply shortage and its impact on the completion of sales during the second half of the 2022 financial year, the Board is very pleased with the growth of the new M2G Cloud business.

During the 2022 financial year, 293 M2G Cloud Solutions were sold (2021: nil) of which 262 (89.4% of the annual total) occurred in the second half of the year. In addition, the Company has deferred revenue of £175k, and open orders of £91k, that will carry over into FY23 as well as £23k of recurring revenue from the M2G Cloud Solutions sold to date to be recognised in FY23. In total, M2G has 2023 revenue identified and charged, but not yet booked, of £289k (July 2021 forward revenue: £43k)

The Board is encouraged that despite the supply chain problems affecting many companies, it has secured revenue which, had it fallen in the year to June 2022 would have resulted in a stable performance year-on-year. It is encouraged, further, that the momentum of revenue is growing through the first half of the Company's financial year to June 2023.

Proton UK Business

Discussions are ongoing with multiple UK oil field owners to identify suitable sites on which to deploy the Proton Technologies Canada Inc. ("Proton") proprietary hydrogen capture technology. In the long term, owners are motivated to develop such hydrogen production facility on their near to end of life fields. The Board believes that this motivation is secular and is likely to grow as the global fuel portfolio adapts to the clear trends in hydrocarbon demand. In the short term, reflecting the current high level of oil prices in the market, field owners have focussed on maximising short term oil production. This has not impacted the momentum behind discussions adversely. The Proton project continues to hold strong prospects for the Group.

COF / b.grn Business

During the financial year to 30 June 2022, the City Oil Field Inc. ("COF") business has been developed in combination with Sabien's development partner b.grn Group Ltd ("b.grn"). Key milestones have been reached including the establishment of a range of partner relationships with funding partners and professional advisors. The latter includes development managers, ESG advisors, and real estate advisors. In consultation with advisers, b.grn has assessed a range of potential sites in England and Wales for the first European COF installation. As previously announced, exclusivity was agreed on a site near Northampton; discussions were held in relation to a site on the Humber Estuary; and most recently an indicative bid was submitted to acquire the ex-Anglesey Aluminium in Anglesey, supported by b.grn funding partners, from the site's administrators. 

Through this work, the Board has developed a strong understanding of the emerging real estate market in key locations in the UK. Within this, the Company and b.grn have developed an advanced assessment of the most efficient sites for the deployment of COF. From this emerging knowledge, the Company and b.grn are now considering actively a number of sites in the UK, and beyond, where b.grn could deploy COF without, necessarily, acquiring the underlying real estate. Investigations into potential sites continue with b.grn's partners. It is likely that the first active deployment will be an initial 24t per day plastic to oil proof of concept plant. 

As a result, the Northampton site's exclusivity has been allowed to lapse. b.grn is not pursuing actively the Humber Estuary site which would have required considerable capital and time investment to make it ready for deployment. Finally, it is b.grn's understanding that it is not one of the leading bidders for the Anglesey Aluminium site on the basis of prices indicated. b.grn awaits any further developments in relation to this site. 

Discussions continue in relation to the Group's option to install a COF site in Saskatchewan on Proton's site. This site has the potential to produce additional benefits in relation to options for the use of offtake oil.

During the year, Sabien charged management fees of £0.15m to b.grn (2021: nil).

Consolidated trading update

The Group's full year consolidated 2022 revenue of £0.83m compares to £0.97m for 2021, a reduction of less than 15%. Sabien has generated consolidated revenue of £0.71m in the second six months of the year under review. This is an increase of 25% on the £0.56m recorded in the same period of 2021. Sabien is also carrying combined revenue of £0.29m into 2023, circa 30% of the total reported in the year to June 2021. A significant component of this carry forward is retained income, giving the Board confidence in the forward visibility of revenue.

As at the balance sheet date, 30 June 2022, Sabien had cash in hand of £0.55m (2021: £1.40m).

Commenting on the 2022 financial year, Richard Parris, Chairman of Sabien, stated:

"During the year under review, despite a challenging supply chain environment, the Company has achieved a solid result for the M2G business once supply chain timing issues are resolved, in addition much development of the COF/b.grn business has been achieved and a fundable business model developed. The Board looks forward to the coming year with considerable confidence.

It is important to remember that the year on which the Board is reporting encompasses two very different trading periods. It is clear to the Board that momentum has accelerated and is building still, notably within M2G and Proton. While COF's development remains more nascent, the Board's knowledge of the available market and the requirements to address it successfully are now well advanced. Sabien enters the year to June 2023 with a confidence backed by results and experience."

For Further Information:

Sabien Technology Group plc

Richard Parris, Executive Chairman 

 

 +44 20 7993 3700 

Allenby Capital Limited (Nominated Adviser)

John Depasquale / Nick Harriss / Vivek Bhardwaj 

 

 

+44 203 328 5656

 

Peterhouse Capital Limited (Broker)

Duncan Vasey / Lucy Williams 

 

+44 207 469 0930

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUNAARUSUBRUR
Date   Source Headline
1st Oct 20127:00 amRNSPreliminary Statement of Final Results
30th Aug 20122:30 pmRNSRetirement of Chairman
10th Jul 20127:00 amRNSPost Close Trading Statement
7th Mar 20127:00 amRNSRe Contract
7th Feb 20127:00 amRNSHalf Yearly Report
1st Feb 20127:00 amRNSRe-organisation of Nominated Adviser and Broker
12th Jan 201212:20 pmRNSDirector Declaration
12th Jan 20129:27 amRNSCapital Reorganisation
9th Jan 20127:00 amRNSNotice of Results
5th Jan 20127:00 amRNSChange of Adviser
19th Dec 201110:54 amRNSDirector Declaration
29th Nov 201110:19 amRNSHolding(s) in Company
24th Nov 20117:00 amRNSResult of AGM
21st Nov 201110:26 amRNSHolding(s) in Company
17th Nov 201111:23 amRNSHolding(s) in Company
4th Nov 20111:50 pmRNSHolding(s) in Company
1st Nov 20117:00 amRNSAnnual Report and Accounts
7th Oct 20117:00 amRNSNew Contract Win
3rd Oct 20117:00 amRNSFinal Results
12th Sep 20117:00 amRNSNew Contract Win
25th Aug 20117:00 amRNSNew Contract Win
11th Jul 20117:00 amRNSPost Year End Trading Update
29th Jun 20111:12 pmRNSM2G sale to US Distributor
2nd Jun 201112:15 pmRNSNotice of Results
8th Apr 201111:28 amRNSM2G sale to US Distributor
2nd Mar 201111:44 amRNSHolding(s) in Company
1st Mar 201111:08 amRNSHolding(s) in Company
7th Feb 20117:00 amRNSHalf Yearly Report
5th Jan 20117:00 amRNSNotice of Results and Trading Update
26th Nov 20107:00 amRNSDirector/PDMR Shareholding
25th Nov 20107:00 amRNSResult of AGM
17th Nov 20107:00 amRNSAward of Contract
12th Nov 20104:12 pmRNSAnnual Financial Report
29th Oct 20107:00 amRNSPreliminary Results
18th Oct 20107:00 amRNSNotice of Results
15th Oct 20107:00 amRNSDirectorate Change
20th Sep 20107:00 amRNSAward of Contract
6th Aug 20107:00 amRNSAward of Contract
5th Jul 20107:00 amRNSAward of Contract
24th Jun 20107:00 amRNSAward of Contract
1st Jun 20107:00 amRNSTrading Statement
17th May 20107:00 amRNSChange of Adviser
1st Apr 201012:37 pmRNSGrant of options
25th Feb 20107:00 amRNSHalf Yearly Report
2nd Dec 20097:00 amRNSNew Contract Win
9th Nov 20097:00 amRNSAdjustment to number of warrants in issue
28th Oct 20097:00 amRNSPreliminary Results - 12 months ended 30 June 2009
14th Oct 20097:00 amRNSPlacing
7th Oct 20097:00 amRNSContract award
28th Sep 200911:40 amRNSAlliance Agreement with Jones Lang LaSalle

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.